European Commission grants marketing authorisation for DAYBU
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Neuren Pharmaceuticals Limited has announced that the European Commission has granted marketing authorization for DAYBU, a treatment for neurobehavioral symptoms of Rett syndrome. This approval allows DAYBU to be marketed across all EU member states and select countries. Neuren's CEO expressed satisfaction for the Rett syndrome community, highlighting the significance of this approval after a long commitment to developing therapies for neurological disorders. Under the licensing agreement, Neuren is set to receive significant financial benefits following the commercial sale of DAYBU.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neuren Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Neuren Pharmaceuticals
- Neuren H1 2026 Financial Results Webinar on 26 August 2026
- Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
- DAYBU recommended for approval in the European Union
- Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
- DAYBUE STIX now broadly available in US for Rett syndrome
Later from Neuren Pharmaceuticals
- Half Yearly Report and Accounts
- Growing royalty anchors Neuren first ever dividend program
- Investor presentation, 26 August 2026
- Dividend/Distribution - NEU
- Corporate Presentation, 2 September 2026
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals